Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period

Therapeutic implications for multiple sclerosis

Kristen A. Rahn, Patricia McLaughlin, Ian Zagon

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30 days of treatment. This study examined the long term effects of the opioid growth factor (OGF, [Met 5]-enkephalin) and a low dose of the opioid antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE. C57BL/6 mice began receiving daily injections of 10 mg/kg OGF (MOG + OGF), 0.1 mg/kg naltrexone (MOG + LDN), or saline (MOG + Vehicle) at the time of EAE induction and continuing for 60 days. In contrast to 100% of the MOG + Vehicle group with behavioral symptoms of EAE, 63% and 68% of the MOG + OGF and MOG + LDN mice expressed disease. Both severity and disease indices of EAE in OGF- and LDN-treated mice were notably decreased from MOG + Vehicle cohorts. By day 60, 6- and 3-fold more animals in the MOG + OGF and MOG + LDN groups, respectively, had a remission compared to MOG + Vehicle mice. Neuropathological studies revealed i) astrocyte activation and neuronal damage as early as day 10 (prior to behavioral symptoms) in all MOG-injected groups, ii) a significant reduction of activated astrocytes in MOG + OGF and MOG + LDN groups compared to MOG + Vehicle mice at day 30, and iii) no demyelination on day 60 in mice treated with OGF or LDN and not displaying disease symptoms. These results indicate that treatment with OGF or LDN had no deleterious long-term repercussions and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological deficits, and iii) prevented the onset of neurological dysfunction across a considerable span of time.

Original languageEnglish (US)
Pages (from-to)243-253
Number of pages11
JournalBrain research
Volume1381
DOIs
StatePublished - Mar 24 2011

Fingerprint

Myelin-Oligodendrocyte Glycoprotein
Naltrexone
Autoimmune Experimental Encephalomyelitis
Opioid Analgesics
Multiple Sclerosis
Intercellular Signaling Peptides and Proteins
Therapeutics
Behavioral Symptoms
Astrocytes
Methionine Enkephalin
Narcotic Antagonists

All Science Journal Classification (ASJC) codes

  • Neuroscience(all)
  • Molecular Biology
  • Developmental Biology
  • Clinical Neurology

Cite this

@article{cff95c98b3334cd5838d12d03e185b01,
title = "Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis",
abstract = "Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30 days of treatment. This study examined the long term effects of the opioid growth factor (OGF, [Met 5]-enkephalin) and a low dose of the opioid antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE. C57BL/6 mice began receiving daily injections of 10 mg/kg OGF (MOG + OGF), 0.1 mg/kg naltrexone (MOG + LDN), or saline (MOG + Vehicle) at the time of EAE induction and continuing for 60 days. In contrast to 100{\%} of the MOG + Vehicle group with behavioral symptoms of EAE, 63{\%} and 68{\%} of the MOG + OGF and MOG + LDN mice expressed disease. Both severity and disease indices of EAE in OGF- and LDN-treated mice were notably decreased from MOG + Vehicle cohorts. By day 60, 6- and 3-fold more animals in the MOG + OGF and MOG + LDN groups, respectively, had a remission compared to MOG + Vehicle mice. Neuropathological studies revealed i) astrocyte activation and neuronal damage as early as day 10 (prior to behavioral symptoms) in all MOG-injected groups, ii) a significant reduction of activated astrocytes in MOG + OGF and MOG + LDN groups compared to MOG + Vehicle mice at day 30, and iii) no demyelination on day 60 in mice treated with OGF or LDN and not displaying disease symptoms. These results indicate that treatment with OGF or LDN had no deleterious long-term repercussions and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological deficits, and iii) prevented the onset of neurological dysfunction across a considerable span of time.",
author = "Rahn, {Kristen A.} and Patricia McLaughlin and Ian Zagon",
year = "2011",
month = "3",
day = "24",
doi = "10.1016/j.brainres.2011.01.036",
language = "English (US)",
volume = "1381",
pages = "243--253",
journal = "Brain Research",
issn = "0006-8993",
publisher = "Elsevier",

}

TY - JOUR

T1 - Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period

T2 - Therapeutic implications for multiple sclerosis

AU - Rahn, Kristen A.

AU - McLaughlin, Patricia

AU - Zagon, Ian

PY - 2011/3/24

Y1 - 2011/3/24

N2 - Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30 days of treatment. This study examined the long term effects of the opioid growth factor (OGF, [Met 5]-enkephalin) and a low dose of the opioid antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE. C57BL/6 mice began receiving daily injections of 10 mg/kg OGF (MOG + OGF), 0.1 mg/kg naltrexone (MOG + LDN), or saline (MOG + Vehicle) at the time of EAE induction and continuing for 60 days. In contrast to 100% of the MOG + Vehicle group with behavioral symptoms of EAE, 63% and 68% of the MOG + OGF and MOG + LDN mice expressed disease. Both severity and disease indices of EAE in OGF- and LDN-treated mice were notably decreased from MOG + Vehicle cohorts. By day 60, 6- and 3-fold more animals in the MOG + OGF and MOG + LDN groups, respectively, had a remission compared to MOG + Vehicle mice. Neuropathological studies revealed i) astrocyte activation and neuronal damage as early as day 10 (prior to behavioral symptoms) in all MOG-injected groups, ii) a significant reduction of activated astrocytes in MOG + OGF and MOG + LDN groups compared to MOG + Vehicle mice at day 30, and iii) no demyelination on day 60 in mice treated with OGF or LDN and not displaying disease symptoms. These results indicate that treatment with OGF or LDN had no deleterious long-term repercussions and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological deficits, and iii) prevented the onset of neurological dysfunction across a considerable span of time.

AB - Endogenous opioids inhibit the onset and progression of experimental autoimmune encephalomyelitis (EAE) with 30 days of treatment. This study examined the long term effects of the opioid growth factor (OGF, [Met 5]-enkephalin) and a low dose of the opioid antagonist naltrexone (LDN) on expression of myelin oligodendrocyte glycoprotein (MOG)-induced EAE. C57BL/6 mice began receiving daily injections of 10 mg/kg OGF (MOG + OGF), 0.1 mg/kg naltrexone (MOG + LDN), or saline (MOG + Vehicle) at the time of EAE induction and continuing for 60 days. In contrast to 100% of the MOG + Vehicle group with behavioral symptoms of EAE, 63% and 68% of the MOG + OGF and MOG + LDN mice expressed disease. Both severity and disease indices of EAE in OGF- and LDN-treated mice were notably decreased from MOG + Vehicle cohorts. By day 60, 6- and 3-fold more animals in the MOG + OGF and MOG + LDN groups, respectively, had a remission compared to MOG + Vehicle mice. Neuropathological studies revealed i) astrocyte activation and neuronal damage as early as day 10 (prior to behavioral symptoms) in all MOG-injected groups, ii) a significant reduction of activated astrocytes in MOG + OGF and MOG + LDN groups compared to MOG + Vehicle mice at day 30, and iii) no demyelination on day 60 in mice treated with OGF or LDN and not displaying disease symptoms. These results indicate that treatment with OGF or LDN had no deleterious long-term repercussions and did not exacerbate EAE, but i) halted progression of disease, ii) reversed neurological deficits, and iii) prevented the onset of neurological dysfunction across a considerable span of time.

UR - http://www.scopus.com/inward/record.url?scp=79952283348&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952283348&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2011.01.036

DO - 10.1016/j.brainres.2011.01.036

M3 - Article

VL - 1381

SP - 243

EP - 253

JO - Brain Research

JF - Brain Research

SN - 0006-8993

ER -